Mark M. Moasser

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Natalia Sergina, Megan Rausch, Donghui Wang et al. · Nature · 2007 · 968 citations · Full text

Signal Transduction, Kinase-inactive Her3, Medicine +7

Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification

Andrew D. Seidman, Monica Fornier, Francisco J. Esteva et al. · Journal of Clinical Oncology · 2001 · 548 citations

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Mark M. Moasser, Andrea Basso, Steven D. Averbuch et al. · PubMed · 2001 · 508 citations

Breast Oncology, Her2-driven Signaling, Tumor Biology +20

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Pamela N. Münster, Kenneth T. Thurn, Scott Thomas et al. · British Journal of Cancer · 2011 · 386 citations · Full text

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

Qing‐Bai She, David B. Solit, Andrea Basso et al. · PubMed · 2003 · 290 citations